{"id":603622,"date":"2024-06-02T04:05:50","date_gmt":"2024-06-02T08:05:50","guid":{"rendered":"https:\/\/platohealth.ai\/weekly-reads-diabetes-gvhd-novo-nordisk-regenerative-medicine-hdacs-the-niche\/"},"modified":"2024-06-02T05:29:30","modified_gmt":"2024-06-02T09:29:30","slug":"weekly-reads-diabetes-gvhd-novo-nordisk-regenerative-medicine-hdacs-the-niche","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/weekly-reads-diabetes-gvhd-novo-nordisk-regenerative-medicine-hdacs-the-niche\/","title":{"rendered":"Weekly reads: diabetes, GvHD, Novo Nordisk & regenerative medicine, HDACs – The Niche","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Do many in the regenerative medicine field have favorite types of stem cells?<\/p>\n
Some seem to think there\u2019s a tension between those working on pluripotent stem cells like iPS cells<\/strong> <\/a>and those working with MSCs<\/strong><\/a>. I don\u2019t see it that way, though.<\/p>\n Whatever stem cells work best for a particular condition should be used and, if successful, celebrated. There are also areas of overlap between these areas, including with MSCs made from iPS cells. Let\u2019s talk about a new paper in this zone of overlap.<\/p>\nRecommended stem cell & regenerative medicine reads<\/h2>\n
\n